Specialized Pro-Resolving Mediators (SPMs): Beyond Omega-3

For most of the twentieth century, the textbook account of inflammation had four signs, one cause, and no ending worth describing. Inflammation was assumed to subside passively once the trigger was cleared — a fire going out because the fuel ran low.

That account is wrong, and the correction is one of the more consequential findings in modern immunology. Resolution is an active, genetically programmed phase with its own signalling molecules, its own receptors, and its own failure modes. ^[1]

The molecules are the specialized pro-resolving mediators: resolvins, protectins, maresins, and lipoxins. And they are built from the omega-3 fatty acids you already know about.

What They Are and Where They Come From

SPMs are enzymatically derived from polyunsaturated fatty acids at the site of inflammation, on demand:

The stereochemistry detail matters more than it sounds: these are not generic antioxidant lipids but specific molecules whose three-dimensional structure determines whether they bind their receptors at all. ^[2] That is the difference between a signalling molecule and a nutrient.

Suppression Versus Resolution

This is the conceptual point worth carrying away, and it is not a marketing distinction.

NSAIDs and corticosteroids block the inflammatory programme. They work, and the cost is built into the mechanism: they impair host defence, slow wound healing, and — in the case of some COX inhibitors — interfere with the synthesis of pro-resolving mediators themselves.

SPMs terminate the programme instead. They stop further neutrophil recruitment, drive macrophages to clear dead cells and debris through efferocytosis, and return the tissue toward baseline. Crucially, they do this without suppressing immunity. ^[1]

The reframing this permits: chronic low-grade inflammation may in many cases be less a matter of excessive signal than of failed resolution — a response that was never given its stop instruction, smouldering because the off-switch is under-supplied.

For anyone stacking anti-inflammatories, that is an argument for covering both halves. Suppression alone treats the symptom of an unresolved response.

What the Human Evidence Actually Shows

Here is where careful reading is required, because the biology is far ahead of the clinical data.

The supplements do raise SPM levels. A randomised, double-blind, placebo-controlled study of enriched marine oil supplements found they increased peripheral blood SPM concentrations and reprogrammed host immune responses — measurable changes in leukocyte behaviour, not just a lipid panel shift. ^[3]

That is a real human result, and it settles the most basic objection: SPM-enriched oils do something detectable in people.

What is missing is the outcome layer. The next question — does raising SPM concentrations improve defined clinical outcomes in a specific condition, at scale, in adequately powered trials — has not been answered. Reviews of SPMs in neuroinflammation describe a compelling mechanistic case and a set of perspectives for clinical application, which is the literature's own way of saying the applications are not yet established. ^[4]

So the honest grade is C: a well-characterised biological effect whose clinical value remains unproven.

What You Are Actually Buying

SPM supplements do not contain resolvins. They contain monohydroxylated precursors — principally 18-HEPE, 17-HDHA, and 14-HDHA — concentrated from marine oil, which your own lipoxygenase enzymes convert into finished mediators.

This is not a technicality. It means the product is an enriched substrate, and its usefulness depends on your enzymatic machinery working, and on your baseline omega-3 status.

Which leads to the practical recommendation nobody selling SPMs makes: fix the base first. If your EPA/DHA intake is low, you are short of raw material for endogenous SPM production, and omega-3 at 2 g/day of combined EPA+DHA costs a fraction as much. SPM concentrates make sense as a layer on top of adequate omega-3 status — not as a replacement for it, and not as a first purchase.

How to Use Them Sensibly

One genuine pathway interaction deserves mention: low-dose aspirin acetylates COX-2 and shifts it toward producing aspirin-triggered resolvins — a documented mechanism rather than a supplement-marketing claim. It is also a prescribing decision with its own bleeding risk, which puts it firmly in a physician's hands rather than a stack's.

The One-Line Version

The discovery that inflammation is switched off actively rather than fading passively is genuinely important, and it explains why suppressing inflammation is not the same as resolving it. The supplements built on that insight raise SPM levels in humans — and have not yet been shown to change clinical outcomes. Get omega-3 right first; treat SPMs as a targeted, time-limited layer, priced accordingly. The full stack is in the inflammation resolution protocol.

Related Reading

• Curcumin Bioavailability: Why Form Matters More Than Dose
• The Inflammation Resolution Stack
• The Bone & Arterial Health Stack